Đang chuẩn bị liên kết để tải về tài liệu:
Combined analysis of PTEN, HER2, and hormone receptors status: Remodeling breast cancer risk profiling

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Phosphatase and tensin homolog (PTEN) loss is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer. However, the clinical value of PTEN as a biomarker in these patients is controversial. We sought to determine whether the benefit of traditional biomarkers testing is improved by the analysis of PTEN status for the identification of high-risk breast cancer. |

TÀI LIỆU LIÊN QUAN

A prediction model for aroma quality of Vietnamese orthodox black teas by combined multivariate analysis of GC/MS and sensory evaluation data

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/ PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: A single-arm meta-analysis based on prospective studies

Does a combined intravenous-volatile anesthesia offer advantages compared to an intravenous or volatile anesthesia alone: A systematic review and meta-analysis

Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: A propensity score matching analysis

Comparative analysis of volatiles difference of Yunnan sun-dried Pu-erh green tea from different tea mountains: Jingmai and Wuliang mountain by chemical fingerprint similarity combined with principal component analysis and cluster analysis

Parametric and working fluid analysis of a combined organic Rankine-vapor compression refrigeration system activated by low-grade thermal energy

Physiological analysis and transcriptome sequencing reveal the effects of combined cold and drought on tomato leaf

Unique miRNAs and their targets in tomato leaf responding to combined drought and heat stress

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer